Clinical trials: Bloodstream Infections
Septic Shock
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
The primary objective of this clinical investigation is to investigate the feasibility and possible benefits of the Alteco® LPS Adsorber in treating patients with septic shock with presumed endotoxemia of abdominal or urogenital…
- Trial name
- ASSET (NCT02335723)
- Testing
- Alteco LPS Adsorber
- Where
- 6 sites in Finland, Norway and 1 more
- Volunteers
- 15 people
- Sponsor
- Alteco Medical AB
Sepsis, Septic Shock
Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million.
- Trial name
- LASSONEO (NCT05707494)
- Testing
- Efferon LPS NEO
- Where
- 7 sites in Russia
- Volunteers
- 78 people
- Sponsor
- Efferon JSC
Bacteremia, Candidemia
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
The purpose of this study is to assess the effectiveness of RaPID/BSI by testing its performance compared to blood cultures collected prospectively from consented subjects.
- Trial name
- NCT04147975
- Testing
- RaPID/BSI Test
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- HelixBind, Inc.
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Septic Shock
First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression
The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.
- Trial name
- RESTORE I (NCT06258291)
- Testing
- Hemosystem REBOOT
- Where
- 2 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- hemotune AG
Sepsis
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction.
- Trial name
- NCT00045760
- Testing
- Drotrecogin alfa (activated)
- Where
- 426 sites in United States, Australia and 30 more
- Sponsor
- Eli Lilly and Company
Sepsis, Severe Sepsis
TRIAGE: TRIage of Sepsis At emerGency dEpartment
Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation Response Syndrome (SIRS) plus a confirmed or suspected infection.
- Trial name
- TRIAGE (NCT02739152)
- Where
- 14 sites in Belgium, France
- Volunteers
- 602 people
- Sponsor
- BioMérieux
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer
Late Onset Neonatal Sepsis, Necrotizing Enterocolitis
Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.
The purpose of this study was to evaluate the safety of a probiotic foodstuff and its influence on emergence and development of natural intestinal flora and the clinical status of premature very low birth weight neonates.
- Conditions
- Late Onset Neonatal Sepsis, Necrotizing Enterocolitis, Infant, Very Low Birth Weight
- Trial name
- NCT02073214
- Testing
- Probiotic
- Volunteers
- 182 people
- Sponsor
- IBSS Biomed S.A.
Systemic Inflammatory Response Syndrome (SIRS), Sepsis
IMproved PREdiction of Severe Sepsis in the Emergency Department
The purposes of this study is to determine whether Heparin Binding Protein (HBP) can be used as a marker of severe sepsis (including septic shock) in patients presenting to the emergency department with suspected infection.
- Conditions
- Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
- Trial name
- IMPRESSED (NCT01392508)
- Where
- 5 sites in United States, Sweden
- Volunteers
- 759 people
- Sponsor
- Axis Shield Diagnostics Ltd
Sepsis, Infections
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
A pre/post interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and/or the staging area/fast track area) with…
- Conditions
- Sepsis, Infections, Tachycardia, Fever
- Trial name
- TIMED (NCT06637904)
- Testing
- TriVerity Test
- Where
- 2 sites in United States
- Volunteers
- 320 people
- Sponsor
- Inflammatix
Sepsis, Community Acquired Pneumonia (CAP)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to…
- Trial name
- NCT06669403
- Testing
- OPT101
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Op-T LLC
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Urinary Tract Infection, Complicated, Acute Pyelonephritis
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired…
- Conditions
- Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02420366
- Where
- 22 sites in United States, Greece and 2 more
- Volunteers
- 257 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Sepsis, Critical Illness
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients
The goal of this clinical trial is to learn if a new medical device that sends electrical signals to the thigh muscles is safe and easy to use for people in the ICU (Intensive Care Unit) who are at risk of losing muscle strength.
- Conditions
- Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness
- Trial name
- ICUAW (NCT07362862)
- Testing
- Electrical Muscle Stimulation System
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Health Discovery Labs
Septic Shock, Endotoxemia
Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Open-label, non-controlled study of standard care plus the TORAYMYXIN PMX-20R (PMX cartridge) in subjects who have endotoxemia and septic shock.
- Trial name
- EUPHORIA (NCT02825329)
- Testing
- TORAYMYXIN PMX-20R
- Sponsor
- Spectral Diagnostics (US) Inc.
Acute Pancreatitis Without Necrosis or Infection
Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05694988
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- Efferon JSC
Central Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN)…
- Trial name
- NCT06822426
- Testing
- (taurolidine and heparin) catheter lock solution, Heparin
- Where
- 24 sites in United States, Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- CorMedix Therapeutics
Candidiasis
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States…
- Trial name
- NCT00037219
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Sepsis
Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.
The main purpose of this study is to compare the early detection of sepsis and the decision, by the Investigator to start or not, or to change, antibiotics in Intensive Care Unit (ICU) patients at high risk of sepsis, based on…
- Trial name
- NCT03474809
- Testing
- Blood sampling
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 296 people
- Sponsor
- Abionic SA